Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure. Issue 3 (26th January 2021)

• Record Type: Journal Article
• Authors: Fujiwara, Takeshi; Hoshide, Satoshi; Tomitani, Naoko; Kanegae, Hiroshi; Kario, Kazuomi
• Other Names: Kario Kazuomi guestEditor.
• Is Part Of: Journal of clinical hypertension. Volume 23:Issue 3(2021)
• Page Start: 687
• Page End: 691
• Publication Date: 2021-01-26
• Subjects: automatic ICT‐based home blood pressure monitoring device -- morning blood pressure -- nocturnal home blood pressure -- valsartan/cilnidipine combination -- valsartan/hydrochlorothiazide combination; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.14199
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: We tested our hypothesis that, in hypertensive patients with higher nocturnal home systolic blood pressure (HSBP) at baseline, a valsartan/cilnidipine (80/10 mg) combination would reduce nocturnal HSBP more markedly than a valsartan/hydrochlorothiazide (80/12.5 mg) combination. Patients measured their nocturnal HSBP over three nights prior to study randomization and at the end of treatment. Sixty‐three and 66 patients comprised the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups; their respective baseline nocturnal HSBP values were 124.3 ± 15.6 and 125.8 ± 15.2 mm Hg ( P = .597). Nocturnal HSBPs were significantly reduced from baseline in both groups. Although the valsartan/hydrochlorothiazide group exhibited a significantly greater reduction in nocturnal HSBP compared to the valsartan/cilnidipine group (−5.0 vs. −10.0 mm Hg, P = .035), interaction between the treatment groups and the baseline nocturnal HSBP levels for the changes in nocturnal HSBP after the treatment periods was significant ( P = .047). The BP‐lowering effect of valsartan/cilnidipine was more dependent on baseline nocturnal HSBP than that of valsartan/hydrochlorothiazide.